Brain Immune Cells Could Hold Key to Alzheimer’s Disease Progression

Scientists have potentially identified a vital clue in unraveling the complexities of Alzheimer’s disease: why some individuals develop dementia while others do not. A recent study in Nature Medicine analyzed brain tissue donated by older adults with varying levels of cognitive function and healthy centenarians. This research suggests that immune cells in the brain may significantly influence the progression of Alzheimer’s disease to dementia.

Brain Immune Cells May Hold the Answer

Alzheimer’s disease is frequently associated with the accumulation of amyloid plaques and tau tangles in the brain. Yet, not everyone with these protein changes experiences dementia. Researchers from Vlaams Instituut voor Biotechnologie, KU Leuven, and Muna Therapeutics in Belgium, in collaboration with the UK Dementia Research Institute, examined brain tissue from people with dementia, healthy older adults, and centenarians. Their focus was on microglia, the brain’s immune cells tasked with protecting and monitoring brain health.

Their findings revealed behavioral differences in microglia during Alzheimer’s development. Initially, microglia entered an inflammatory state associated with amyloid plaques. As the disease progressed, some microglia transitioned to a different immune state in the presence of tau buildup and brain cell damage. This transition might be crucial in determining whether Alzheimer’s-related changes lead to dementia.

Dr. Steve Allder, a consultant neurologist not involved in the study, highlighted the significance of the research, stating that maintaining a healthy immune response in the brain could be as essential as removing amyloid plaques. He suggested that comprehending how protective mechanisms function might enable delaying or preventing Alzheimer’s symptoms despite pathology presence.

Not Everyone Resists Alzheimer’s the Same Way

The study also discovered that individuals who maintained cognitive sharpness despite Alzheimer’s pathology did not exhibit uniform patterns. Some older adults with amyloid plaques did not show dementia due to early microglial response, but they never transitioned to the later immune state linked to disease progression. Interestingly, healthy centenarians activated the later immune response without a strong connection to tau buildup.

This implies that Alzheimer’s resilience may not solely rely on avoiding disease-related brain changes. It could depend on how the brain responds to and adapts to these changes. Study corresponding author Professor Mark Fiers emphasized that better understanding the brain’s resistance to the disease could provide new paths for therapies to prevent neurodegeneration and dementia.

The findings are expected to shape future Alzheimer’s treatment approaches. Researchers might shift their focus from only targeting amyloid plaque removal to influencing microglia and preserving immune responses linked to resilience. Niels Plath, chief scientific officer of Muna Therapeutics, expressed enthusiasm for exploring microglial transitions to identify new therapeutic strategies to delay or prevent disease progression.